Clinical trial
A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
NCT04674813 is registered in ClinicalTrials.gov with Juno Therapeutics, a Subsidiary of Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Multicenter, Open-Label Study of CC-95266 in Subjects With Relapsed and/or Refractory Multiple Myeloma
- Lead sponsor
- Juno Therapeutics, a Subsidiary of Celgene
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 24, 2021
- Completion date
- December 22, 2025
- Enrollment
- 130 (actual)
- Sites
- 10
Conditions
As the registry lists them; a condition with its own page is linked.